AstraZeneca: Tezspire Shows Positive Phase III Results in Eosinophilic Esophagitis
October 21, 2026
October 21, 2026
WILMINGTON, Delaware, Oct. 21 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week
20 October 2026
First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remissio . . .
* * *
TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week
20 October 2026
First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remissio . . .